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Introduction/aim: The supraphysiologic chloride concentration of normal saline may
contribute to acute kidney injury (AKI). Balanced crystalloids can decrease chloride
concentration and AKI in critically ill patients. We aim to test the hypothesis that, in
patients with predicted severe acute pancreatitis (pSAP), compared with saline, fluid
therapy with balanced crystalloids will decrease plasma chloride concentration.
Methods/Design: This is amulticenter, stepped-wedge, cluster-randomized, controlled
trial. All eligible patients presenting to the 11 participating sites across China during the
study period will be recruited. All sites will use saline for the first month and sequentially
change to balanced crystalloids at the pre-determined and randomly allocated time
point. The primary endpoint is the plasma chloride concentration on day 3 of enrollment.
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Secondary endpoints will include major adverse kidney events on hospital discharge
or day 30 (MAKE 30) and free and alive days to day 30 for intensive care admission,
invasive ventilation, vasopressors, and renal replacement therapy. Additional endpoints
include daily serum chloride and sequential organ failure assessment (SOFA) score over
the first seven days of enrollment.
Discussion: This study will provide data to define the impact of normal saline vs.
balanced crystalloids on plasma chloride concentration and clinical outcomes in pSAP
patients. It will also provide the necessary data to power future large-scale randomized
trials relating to fluid therapy.
Ethics and Dissemination: This study was approved by the ethics committee
of Jinling Hospital, Nanjing University (2020NZKY-015-01) and all the participating
sites. The results of this trial will be disseminated in peer-reviewed journals and at
scientific conferences.
Trial registration: The trial has been registered at the Chinese Clinical Trials
Registry (ChiCTR2100044432).
Keywords: acute pancreatitis, saline, crystalloid, acute kidney injury, intravenous fluid
INTRODUCTION
The most important determinant of mortality in patients with
acute pancreatitis (AP) is organ failure (1). Renal failure or acute
kidney injury (AKI) occurs in 25–59% of patients with severe AP
(2, 3). It may be due to several factors, including hypovolemia,
hypoxemia, pancreatic proteolytic enzymes, impairment of renal
microcirculation, decreased renal perfusion pressure, tissue
edema, and/or intrabdominal hypertension (4–6). Maintaining
normovolaemia by timely and adequate fluid therapy to
preserve organ perfusion is considered the cornerstone of the
management of AP in the acute phase (7–9).
Normal saline (NS or 0.9% sodium chloride) is the most
frequently used isotonic crystalloid fluid for resuscitation in
the acute setting around the world (10). Because the chloride
concentration of NS (154 mmol per liter) is significantly higher
than plasma chloride concentration (94–111 mmol per liter),
there is a risk of hyperchloremic metabolic acidosis. The risk
of this increases with systemic inflammation and impaired
renal perfusion through multiple mechanisms (11). However,
the clinical impact of the increased chloride load with NS
resuscitation is not fully understood. There is some evidence that
it increases the risk of AKI and the need for renal replacement
therapy (RRT) in critically ill patients (12, 13), but there is no
reliable data in AP patients.
Balanced crystalloid fluids are an alternative to NS, and some
current guidelines recommend Lactated Ringers (LR) for early
resuscitation, but there is a lack of high-quality evidence (7, 8,
14). Previous studies showed that LR resuscitation can decrease
inflammatory markers but did not improve clinical outcomes
in patients with predominantly mild AP (15–17). These studies
did not report changes in plasma chloride or the incidence of
AKI. Our previous study showed that aggressive resuscitation
and increased chloride load during the first 24 hours were risk
factors for new-onset AKI in patients with moderately severe
and severe AP (18). This study aims to compare the impact
of NS and a balanced crystalloid fluid on the plasma chloride




The primary objective of the CLEVER-AP trial is to determine
whether, compared to NS, balanced crystalloids significantly
reduce plasma chloride concentration in patients with pSAP.
The secondary objective is to determine whether a lower
plasma chloride concentration is associated with reduced renal
dysfunction and improved clinical outcomes.
Study Design
The present study is an investigator-initiated, stepped-wedge,
cluster-randomized trial, in which each participating hospital
will begin in the control phase (patients receiving NS)
and transition to the intervention phase (patients receiving
balanced crystalloids) at randomly assigned time points (wedge).
This trial was registered at the Chinese Clinical Trials
Registry (ChiCTR2100044432).
Trial Committees
A Trial Management Committee (TMC) was formed comprising
the primary investigators, supported by all the other co-
investigators (clinical and non-clinical) from the participating
sites and members of the Chinese Acute Pancreatitis Clinical
Trials Group (CAPCTG) coordinating center. The TMC is
responsible for the day-to-day running and management of the
trial. An expert clinical panel consisting of experts from the
CAPCTG was organized to provide governance and audit the
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study (some are not from the participating sites). This panel
will also assist with crucial clinical decision-making, such as the
introduction of RRT.
A writing and publication committee is responsible for
drafting the manuscript and submission of the manuscript to
proper academic journals. It will also decide on the authorship
of this study.
Study Population
All adult patients with AP admitted to the participating sites will
be assessed for eligibility after admission. This trial will include
all patients from the 11 hospitals who met the eligibility criteria
during the enrollment period.
Eligibility Criteria
The inclusion and exclusion criteria are as follows:
Inclusion Criteria
1. Diagnosis of acute pancreatitis (19): symptoms and signs of
acute pancreatitis based on abdominal pain, serum amylase at
least three times the upper limit of the normal range, and/or
characteristic findings on computed tomography;
2. Predicted severe acute pancreatitis, based on APACHE-II
score≥8 and CRP>150 mg/L.
3. Recruitment within 72 h from the onset of the symptoms;
4. Age between 18 to 70 yrs old;
Exclusion Criteria
1. Patients with chronic renal disease [All patients with an eGFR
<60 ml/min/1.73 m2 for three months are defined as having
chronic kidney disease (20)].
2. Patients who need emergent RRT at the time of admission.
The indication for RRT will be according to the criteria
described by Bellomo et al. (21).
3. Patients who are pregnant or lactating at the time
of enrollment.
4. Patients who undergo RRT before admission.
5. Patients receiving percutaneous or transmural drainage for
pancreatic necrotic collections or surgery before admission or
requiring emergency surgery due to abdominal compartment
syndrome, bowel ischemia, etc., at admission.
6. Patients present with fulminant multiple organ failure with
predicted death within 24–48 hrs (e.g., severe respiratory
failure, severe systemic circulatory failure, coma, or other
dangerous symptoms that are difficult to reverse).
7. Patients with a known history of severe cardiovascular,
respiratory, renal, hepatic, hematologic, or immunologic
disease defined as (1) greater thanNewYorkHeart Association
class II heart failure, (2) active myocardial ischemia, or
(3) cardiovascular intervention within previous 60 days,
(4) history of cirrhosis or (5) severe chronic obstructive
pulmonary disease requiring home oxygen.
Randomization Methods
We used a computer-generated randomization scheme to
determine the order in which each participating site crosses over
from the control phase to the intervention phase. According to
the stepped wedge design, all sites will initiate recruitment using
NS for fluid therapy in the first month. Every month thereafter,
one hospital will be randomized to use balanced crystalloids
without a transition period. The assignment of patients will
depend on their admission date (Figure 1).
This study is open-label. Therefore, no blinding method will
be applied to the investigators. However, study participants,
operators who perform the blood test, and data analysts will be
masked to the allocation sequence. Study investigators will be
blinded to the allocation sequence, with only the next hospital
randomized for rollout being revealed a week before each
transition time point.
Sample Size, Centers, and Recruitment
According to the previous study, the standard deviation of
serum chlorine in patients with severe acute pancreatitis is
conservatively estimated at 6mmol/L (22). A total of 240 patients
will be recruited from 11 centers within 12 months (20 patients
per month). They will provide 90% power to detect the serum
chlorine difference of 1.5 mmol/L or more between the balanced
crystalloid and the saline group on the basis of within period
intra-class correlation coefficient (ICC) of 0.05 and cluster auto-
correlation (CAC) of 0.5.
The starting date of patient recruitment was Apr 1st, 2021, and
the planned finishing date is Mar 31st, 2022. The follow-up will be
finished after the discharge of the last recruited patient.
Study Interventions
Study protocol determines only the choice of intravenous
isotonic crystalloid: 0.9% sodium chloride or other
hyperchloremic solutions (saline group) vs. the Sterofundin
ISOTM (balanced crystalloid group). The compositions
of each crystalloid solution are given in Additional file 1:
Supplementary Table 1.
Group 1: Balanced Crystalloid Fluid
Patients will receive Sterofundin ISOTM (B. Braun) whenever
isotonic intravenous fluid administration is ordered by the
treating clinical team for seven days after enrollment or until
discharge or death (whichever happens first).
Group 2: NS Fluid
Patients assigned to saline fluid will receive 0.9% Saline or other
hyperchloremic solutions whenever isotonic intravenous fluid
administration is ordered by the treating clinical team for seven
days after enrollment or until discharge or death (whichever
happens first).
Principles for Fluid Therapy
For patients who are not resuscitated before enrollment, fluid
resuscitation will be initiated based on the 2013 IAP/APA
guidelines (7). Briefly, 5–10 ml/kg/h of the study crystalloids
should be used until resuscitation goals are reached. The
resuscitation targets include one or more of the following:
(1) non-invasive clinical targets of heart rate <120/min, mean
arterial pressure between 65 and 85 mmHg, and urinary output
>0.5ml/kg/h, (2) invasive clinical targets of stroke volume
variation, and intrathoracic blood volume determination, and
(3) biochemical targets of hematocrit 35–44% (7). For patients
who are resuscitated before enrollment, the assessment of fluid
responsiveness and the rate of crystalloid prescription will be
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FIGURE 1 | Crystalloid assignment during the trial. All sites will initiate the trial with 0.9% saline (S) as the intravenous fluid at the first month and sequentially change
over to balanced crystalloids (B) without a transition period.
determined by the treating physicians based on the resuscitation
goals mentioned above.
Management of Acute Pancreatitis
Patients will be managed by the local clinical team at each
participating site based on the 2013 IAP/APA guidelines (7),
and most clinical decisions will be left to them. All patients
will receive initial standard treatment, including early enteral
nutrition (start within 48 h after admission), routine medical
treatment (antibiotics and sedatives as needed, organ support
like mechanical ventilation, and vasopressors commenced at the
discretion of the treating team. Patients with AKI (≥1.5x increase
in creatinine above known baseline value) and meet predefined
specific criteria described by Bellomo et al. (21) will be eligible for
the introduction of RRT. Suspected infection of local pancreatic
collections will be treated by the’step-up’ approach, starting with
percutaneous or transmural drainage followed by debridement
using the preferred technique at each participating site.
Endpoints
Primary Endpoint
The primary endpoint is plasma chloride concentration on the
morning of day 3. The day 3 chloride will be the chloride
measured in the morning bloods on the third day after
enrollment, with the day of enrollment labeled day 1, the next
day labeled day 2, and the following day labeled day 3. Thus,
the measurement of day3 chloride will typically be 36–48 h
from enrollment. The time point is chosen because high-rate
intravenous fluid administration is expected during this period
(initial 24–48 h), as early aggressive hydration is recommended
in AP patients (23).
Secondary Endpoints Outcome Measures
Part I: Key Secondary Endpoints
MAKE 30 (Major Adverse Kidney Events by hospital discharge
or day 30) and its components, including death, new receipt
of RRT, or persistent renal dysfunction during the same
time interval.
Part II: Clinical Points
1. Requirement of ICU admission during the index admission.
2. Intensive care unit free and alive days to
day 30.
3. Hospital free and alive days to day 30.
4. Ventilator free and alive days to day 30.
5. Vasopressor free and alive days to day 30.
6. RRT-free and alive days to day 30.
7. New-onset organ dysfunction as judged by SOFA score
[Time Frame: 30 days of enrollment].
8. Daily SOFA score from day1 to day7.
9. Daily SIRS score from day1 to day7.
10. Daily assessment of abdominal pain (VAS score) from day1
to day7.
11. Intravenous morphine equivalent dose from day1 to day7.
12. Occurrence of infected pancreatic necrosis (IPN) during the
index admission.
13. Occurrence of sepsis during the index admission.
14. Occurrence of intra-abdominal bleeding during the
index admission.
15. Occurrence of gastrointestinal fistula during the
index admission.
16. All-cause mortality during the index admission.
17. Requirement of open surgery during the index admission.
Part III: Biochemical Endpoints
1. Highest creatinine in the first seven days.
2. Highest serum chloride in the first seven days
of enrollment.
3. Daily serum chloride from day1 to day 7.
4. Daily serum bicarbonate from day1 to day 7.
5. Plasma NGAL concentration at day1, day2, day3, and day5.
6. Healthcare resource use (hospital expenditure) during the
index admission.
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Monitored Parameters and Data Collection
A web-based electronic database (Unimed Scientific, Wuxi,
China) will be used for data collection and storage. All data
are inputted by the nominated investigator at each participating
site. Training for data entry was arranged by the provider for
all nominated investigators by the CAPCTG coordinating center
before study commencement. The data required to be collected
during different phases are shown in Figure 2. The CAPCTG
coordinating center will be responsible for data management,
safety, privacy, and quality.
Statistical Analysis
The reporting and presentation of this trial will follow the
CONSORT guidelines for stepped-wedge trials (24). Based on
the principle of intention to treat (ITT), a full-analysis set (FAS)
will be performed on the population with outcome reporting
(day3 chloride concentration). FAS will be used for the analysis of
baseline characteristics and main therapeutic interventions. The
safety set (SS) will include all enrolled patients for assessing the
safety profile of the intervention.
Descriptive statistics will be used to assess anymarked baseline
differences in demographics or outcome measures between the
two groups, taking clustering into account. Comparisons of
binary outcomes will be expressed as relative risk with 95%
confidence intervals and comparisons of continuous outcomes
as mean differences together with 95% confidence intervals.
Between-group comparisons will be made using generalized
linear mixed-model (GLMMs) with a hospital-level random
effect to address clustering by hospital and random slopes of
time to account for temporal effects, as delineated by Hussey and
Hughes. Two-sided 5% significance levels will be used to identify
statistically significant results. All confidence intervals reported
will be 95% confidence intervals.
A series of subgroup analyses will be conducted for the
evaluation of the primary endpoint: age (dichotomized at 60 years
old), referral or non-referral, presence of AKI at enrollment, and
presence of organ failure at enrollment.
For any possible missing data, we assume the data is missing
at random while performing analyses by GLMM. Moreover,
a series of sensitivity analyses after imputing the missing
primary outcome using worse-case (i.e., values at baseline), Last
Observation Carried Forward (LOCF), and multiply imputation
will be used to validate and test the robustness of our trial result.
Adverse Events
All the participating sites and clinical teams will be required to
report all adverse events to the CAPCTG coordinating center.
An independent data safety and monitoring board (DSMB)
(consisting of a surgeon, an intensivist, and a statistician) will
oversee all aspects of patient safety. The DSMB will review all
the safety profiles regularly (every 2 months) during the study
period. Adverse events (AE) will be reported in a uniform format
through the electronic data capture system.
DISCUSSION
The best crystalloid for the early resuscitation of patients
with AP remains controversial. The CLEVER-AP trial will,
for the first time, provide evidence regarding the effects of
normal saline and balanced crystalloid fluid on plasma chloride
concentration and AKI in patients with pSAP. The findings of
this trial will have direct clinical consequences as it will provide
definitive evidence.
MAKE30 is identified as a key clinical endpoint, and it
has been used successfully in several fluid trials (12, 25).
MAKE30 is the composite of death, new RRT, or persistent
renal dysfunction (PRD), which is recommended by the
National Institute of Diabetes and Digestive and Kidney Diseases
(NIDDK) workgroup for capturing effects of the short-term or
longer-term evolution of AKI (26, 27). As such, it is a patient-
centered and highly relevant endpoint for clinical research.
Adopting MAKE30 as a key secondary endpoint will allow
comparison with other major trials conducted with different
patient populations.
The stepped-wedge cluster randomized design is adopted for
the CLEVER-AP trial based on both methodology and clinical
merits it could provide. From the methodology perspective, it
uses the hospital as the entity of randomization because this will
minimize the risk of treatment contamination and could greatly
reflect the real-life practice across each hospital compared to
randomization at the patient or physician level. Moreover, this
design could model and assess the underlying temporal trends
of the intervention with all hospitals accessing the intervention
at the end of the rollout period. From the clinical perspective,
since massive intravenous fluid infusion is essential and crucial in
managing early acute pancreatitis, randomization at the patient
level would make the intervention (fluid infusion with different
types of crystalloids) vulnerable to misuse, potentially leading
to contamination (12, 28). Moreover, the routine consent-and-
randomization process in patient-level randomized trials takes
a lot of time, during which no one knows what fluid should be
used before randomization. Therefore, intravenous fluid before
randomization, which could be massive, could significantly
confound the trial results.
The CLEVER-AP trial is sponsored by Jinling Hospital
of Nanjing University, which is the national referral center
for AP, admitting more than 800 cases of AP annually. The
trial will be coordinated by the CAPCTG coordinating center
(capctg.medbit.cn), which is capable of and experienced in
conducting nationwide trials (29, 30).
In conclusion, the CLEVER-AP trial aims to evaluate the
effects of balanced crystalloids vs. NS on plasma chloride
concentration, major adverse kidney events, and clinical
outcomes in predicted severe acute pancreatitis patients.
STRENGTHS AND LIMITATIONS
Strengths
1. This is a stepped-wedge cluster-randomized, multicenter,
controlled trial providing high-level evidence about the
impact of NS and a balanced crystalloid on plasma
chloride concentration and renal function/AKI/renal failure,
a significant consequence of severe AP.
2. The data will be reviewed by an independent data safety
monitoring board (DSMB) to ensure the participants’ safety.
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FIGURE 2 | Schedule of enrollment, interventions, and assessments. MAKE denotes major adverse kidney events. PASS denotes pancreatitis activity scoring system.
Limitations
1. Mild acute pancreatitis patients whomay also benefit from the
use of balanced crystalloids will not be included;
2. The study sample size is relatively small and not sufficiently
powered to detect a difference in patient-centered outcomes
like MAKE 30.
Trial Status
The CLEVER-AP trial will be conducted between Apr 1st, 2021,
to Mar 31st, 2022.
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